AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
This award includes $12.7 million for core research funding and the potential of an additional $9 million to support clinical trials of promising treatments. This award marks the fifth time the Case Western Reserve University (CWRU)/University Hospitals (UH) AIDS Clinical Trials Unit has received NIAID funding since it began operating in 1987.
"We are very proud to have received this competitive award," said co-principal investigator Michael Lederman, MD, the Scott R. Inkley Professor of Medicine and associate director of the Center for AIDS Research at Case Western Reserve School of Medicine and infectious disease specialist at UH Case Medical Center. "It shows a level of confidence in our unit that encourages and inspires us."
Benigno Rodriguez, MD, co-principal investigator and associate professor of medicine at Case Western Reserve School of Medicine and infectious disease physician at UH Case Medical Center, agreed.
"This award will not only allow us to continue our studies of treatment strategies," he said "It assures we can maintain the outstanding team that has made all this success possible."
The CWRU/UH AIDS Clinical Trials Unit is one of 37 worldwide that will conduct human studies to advance knowledge of the mechanisms of HIV-related diseases, the prevention of HIV acquisition, and the treatment of HIV/AIDS and its complications.
In addition, Cleveland's unit is one of only two U.S. centers funded as study sites for three different research networks clinical treatment trials and prevention trials using microbicides and promising HIV vaccines. (The other center is at the University of California, San Francisco.)
The federal gra
|Contact: Jessica Studeny|
Case Western Reserve University